Skip to main content
Log in

Phase 1 study of high-dose hydroxyurea in lung cancer

  • Original Articles
  • High-Dose Hydroxyurea, Lung Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The in vitro chemosensitivity of a human lung cancer cell line to hydroxyurea (HU) was measured, and concentrations of 1 m M HU effected 99% inhibition of cell growth. Therefore, infusions designed to achieve serum levels of over 1 m M HU were assessed by escalating doses of hydroxyurea (HU) administered by continuous i. v. infusion at 3-weekly intervals in 18 patients with lung cancer. Dose increments from 24 g in 24 h to 48 g in 48 h were achieved. The dose-limiting toxicity at 48 g in 48 h was myelosuppression. Oral administration of HU did not result in sustained levels comparable to those achieved with continuous infusion. Two patients showed evidence of radiological response after three courses of treatment. Serum HU profiles were monitored after administration i. v. in 26 courses and after administration p. o. in 5 courses of treatment. A mean serum level of >1 mM was achieved by 6 h and then maintained during treatment. The standard error of the mean area under the curve showed an overall 5% variation. HU can be given in doses up to 48 g in 48 h 3-weekly with manageable tissue and bone marrow toxicity, and the in vivo blood levels attained are equal to those necessary for effective cell inhibition in an appropriate in vitro model. This schedule provides a basis for combination studies with other cytotoxics or for use of HU as a DNA repair inhibitor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arul IM (1970) Therapeutic effects of hydroxyurea: experience with 118 patients with inoperable tumours. Cancer 25: 705–714

    Google Scholar 

  2. Belt RJ, Hass CD, Kennedy J, Taylor S (1980) Studies of hydroxyurea administered by continuous infusion. Cancer 46: 455–462

    Google Scholar 

  3. Borenfreund E, Krim M, Bendlich A (1969) Chromosomal aberrations induced by hyponitrite and hydroxylamine derivatives. J Natl Cancer Inst 32: 667–680

    Google Scholar 

  4. Creasy WA, Capizzi RL, DeConti RC (1970) Clinical and biochemical studies of high dose intermittent therapy of solid tumours with hydroxyurea (NSC-32065). Cancer Chemother Rep 54: 191–194

    Google Scholar 

  5. De Jaeger R, Longeval E, Klastersky J (1980) High dose cisplatin with fluid and mannitol induced diuresis in advanced lung cancer: a phase II trial of the EORTC Lung Cancer Working Party. Cancer Treat Rep 64: 1341–1346

    Google Scholar 

  6. Donehower RC (1982) Hydroxyurea. In: Chubner B (ed), Pharmacological principles of cancer treatment. Saunders, Philadelphia, pp 269–275

    Google Scholar 

  7. Fabricius E, Rajewsky MF (1971) Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Et Clin Biol 16: 679–683

    Google Scholar 

  8. Frindel E, Malaise E, Tubiana M (1968) Cell proliferation kinetics in five human solid tumours. Cancer 22: 611–620

    Google Scholar 

  9. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP (1973) In vitro cultivation of human tumours: establishment of cell lines derived from a series of solid tumours. J Natl Cancer Inst 51: 1417–1423

    CAS  PubMed  Google Scholar 

  10. Kaung DT, Walsh WS, Sbor S, Patno ME (1968) Hydroxyurea in therapy for nonresectable cancer of the lung. Cancer Chemother Rep 52: 271–274

    Google Scholar 

  11. Kennedy BJ (1972) Hydroxyurea therapy in chronic myelogenous leukaemia. Cancer 29: 1052–1056

    Google Scholar 

  12. Krakoff IH (1975) Clinical and pharmacological effects of hydroxyurea. In: Sartorelli AC, Johns DG (eds) Handbuch der experimentellen Pharmakologie, vol 38/II. Springer, Belin Heidelberg New York, pp 789–792

    Google Scholar 

  13. Landgren RC, Hussey DH, Barkley HT, Samuels ML (1974) Split course irradiation compared to split course irradiation plus hydroxurea in operable bronchogenic carcinoma: a randomised study of 53 patients. Cancer 34: 1598–1601

    Google Scholar 

  14. Lerner HJ, Beckloff GL (1965) Hydroxyurea administered intermittently. JAMA 192: 138–140

    Google Scholar 

  15. Le Par E, Faust DS, Brady LW, Beckloff GL (1967) Clinical evaluation of the adjunctive use of hydroxyurea in radiation therapy of carcinoma of the lung. A comparative study. Radiol Clin 36: 32–40

    Google Scholar 

  16. Martin RF, Radford J, Pardee M (1977) Accumulation of short DNA fragments in hydroxyurea treated mouse L cells. Biochem Biophys Res Commun 74: 9–15

    Google Scholar 

  17. Pearson CM (1983) In: Downes CS, Collins ARS, Johnson RT. International Workshop on DNA Repair. Mutat Res 112: 75–83

    Google Scholar 

  18. Sinclair WJ (1965) Hydroxyurea: differential lethal effects on cultured mammalian cells during the cell cycle. Science 150: 1729–1731

    Google Scholar 

  19. Skipper HE, Schabel FM Jr, Wilcox WS (1967) Experimental evaluation of potential anticancer agents: XI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukaemia cells. Cancer Chemother Rep 51: 125–141

    Google Scholar 

  20. Synder RD (1984) Inhibitors of ribonucleotide reductase alter DNA repair in human fibroblasts through specific depletion of purine deoxynucleotide triphosphates. Cell Biol Toxicol 1: 81–93

    Google Scholar 

  21. Thelander L, Reichard P (1979) Reduction of ribonucleotides. Annu Rev Biochem 48: 133–158

    Google Scholar 

  22. Thurman WG, Bloedow C, Howe CD, Levin WC, Davis P, Lane M, Sullivan MP, Griffith KM (1963) A phase I study of hydroxyurea. Cancer Chemother Rep 29: 103–107

    Google Scholar 

  23. Tubiana M, Malaise EP (1976) Growth rate and cell kinetics in human tumours. In: Symington T, Carter RL (eds) Scientific foundations of oncology. Heinemann, London, pp 119–125

    Google Scholar 

  24. Wawra E, Wintersberger E (1983) Dose hydroxyurea inhibit DNa replication in mouse cells by more than one mechanism? Mol Cell Biol 3: 297–304

    Google Scholar 

  25. World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO, Geneva

    Google Scholar 

  26. Young CW, Hodge S (1964) Hydroxyurea: inhibitory effect on DNA metabolism. Science 146: 1172–1174

    Google Scholar 

  27. Young CW, Schachetman G, Karnofsky DA (1967) Hydroxy urea-induced inhibition of deoxyribonucleotide synthesis: studies in intact cells. Cancer Res 27: 526–534

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Veale, D., Cantwell, B.M.J., Kerr, N. et al. Phase 1 study of high-dose hydroxyurea in lung cancer. Cancer Chemother. Pharmacol. 21, 53–56 (1988). https://doi.org/10.1007/BF00262739

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00262739

Keywords

Navigation